Patents by Inventor Myra Noorely Widjojoatmodjo
Myra Noorely Widjojoatmodjo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220133878Abstract: Methods of inducing a safe immune response against respiratory syncytial virus (RSV) in a human subject in need thereof, including administering to the subject a composition including recombinant adenovirus including a nucleic acid encoding an RSV Fusion (F) protein including the amino acid sequence of SEQ ID NO: 1, and a pharmaceutically acceptable carrier, in a total dose of from about 1×101° to about 2×10? viral particles (vp), are described.Type: ApplicationFiled: January 20, 2022Publication date: May 5, 2022Inventors: Myra Noorely WIDJOJOATMODJO, Olivier GODEAUX, Kristi Lynn WILLIAMS, Benoit Christophe Stephan CALLENDRET, Jerald C. SADOFF
-
Patent number: 11229695Abstract: Methods of inducing a safe immune response against respiratory syncytial virus (RSV) in a human subject in need thereof, including administering to the subject a composition including recombinant adenovirus including a nucleic acid encoding an RSV Fusion (F) protein including the amino acid sequence of SEQ ID NO: 1, and a pharmaceutically acceptable carrier, in a total dose of from about 1×1010 to about 2×1011 viral particles (vp), are described.Type: GrantFiled: September 13, 2018Date of Patent: January 25, 2022Assignee: Janssen Vaccines & Prevention B.V.Inventors: Myra Noorely Widjojoatmodjo, Olivier Godeaux, Kristi Lynn Williams, Benoit Christophe Stephan Callendret, Jerald C. Sadoff
-
Patent number: 10967014Abstract: The invention relates to pneumoviral virions comprising a viral genome that has a mutation in a gene coding for a protein that is essential for infectivity of the pneumovirus, whereby the mutation causes a virus produced from only the viral genome to lack infectivity, and whereby the virion comprises the protein in a form and in an amount that is required for infectivity of the virion. The invention also relates to methods for producing the pneumoviral virions and for using the virions in the treatment or prevention of pneumoviral infection and disease. A preferred pneumoviral virion is a virion of Respiratory Syncytial Virus in which preferably the gene for the G attachment protein is inactivated and complemented in trans.Type: GrantFiled: January 9, 2018Date of Patent: April 6, 2021Assignee: De Staat der Nederlanden, vert. door de minister van VWSInventors: Willem Luytjes, Myra Noorely Widjojoatmodjo
-
Publication number: 20200197509Abstract: Methods of inducing a safe immune response against respiratory syncytial virus (RSV) in a human subject in need thereof, including administering to the subject a composition including recombinant adenovirus including a nucleic acid encoding an RSV Fusion (F) protein including the amino acid sequence of SEQ ID NO: 1, and a pharmaceutically acceptable carrier, in a total dose of from about 1×1010 to about 2×1011 viral particles (vp), are described.Type: ApplicationFiled: September 13, 2018Publication date: June 25, 2020Inventors: Myra Noorely WIDJOJOATMODJO, Olivier GODEAUX, Kristi Lynn WILLIAMS, Benoit Christophe Stephan CALLENDRET, Jerald C. SADOFF
-
Publication number: 20180207211Abstract: The invention relates to pneumoviral virions comprising a viral genome that has a mutation in a gene coding for a protein that is essential for infectivity of the pneumovirus, whereby the mutation causes a virus produced from only the viral genome to lack infectivity, and whereby the virion comprises the protein in a form and in an amount that is required for infectivity of the virion. The invention also relates to methods for producing the pneumoviral virions and for using the virions in the treatment or prevention of pneumoviral infection and disease. A preferred pneumoviral virion is a virion of Respiratory Syncytial Virus in which preferably the gene for the G attachment protein is inactivated and complemented in trans.Type: ApplicationFiled: January 9, 2018Publication date: July 26, 2018Applicant: De Staat der Nederlanden, vert. door de minister van VWSInventors: Willem LUYTJES, Myra Noorely WIDJOJOATMODJO
-
Patent number: 9889168Abstract: The invention relates to pneumoviral virions comprising a viral genome that has a mutation in a gene coding for a protein that is essential for infectivity of the pneumovirus, whereby the mutation causes a virus produced from only the viral genome to lack infectivity, and whereby the virion comprises the protein in a form and in an amount that is required for infectivity of the virion. The invention also relates to methods for producing the pneumoviral virions and for using the virions in the treatment or prevention of pneumoviral infection and disease. A preferred pneumoviral virion is a virion of Respiratory Syncytial Virus in which preferably the gene for the G attachment protein is inactivated and complemented in trans.Type: GrantFiled: July 31, 2015Date of Patent: February 13, 2018Assignee: De Staat der Nederlanden, vert, door de minister van VWSInventors: Willem Luytjes, Myra Noorely Widjojoatmodjo
-
Publication number: 20150329833Abstract: The invention relates to pneumoviral virions comprising a viral genome that has a mutation in a gene coding for a protein that is essential for infectivity of the pneumovirus, whereby the mutation causes a virus produced from only the viral genome to lack infectivity, and whereby the virion comprises the protein in a form and in an amount that is required for infectivity of the virion. The invention also relates to methods for producing the pneumoviral virions and for using the virions in the treatment or prevention of pneumoviral infection and disease. A preferred pneumoviral virion is a virion of Respiratory Syncytial Virus in which preferably the gene for the G attachment protein is inactivated and complemented in trans.Type: ApplicationFiled: July 31, 2015Publication date: November 19, 2015Applicant: De Staat der Nederlanden, vert. door de minister van VWSInventors: Willem LUYTJES, Myra Noorely WIDJOJOATMODJO
-
Patent number: 9107939Abstract: The invention relates to pneumoviral virions comprising a viral genome that has a mutation in a gene coding for a protein that is essential for infectivity of the pneumovirus, whereby the mutation causes a virus produced from only the viral genome to lack infectivity, and whereby the virion comprises the protein in a form and in an amount that is required for infectivity of the virion. The invention also relates to methods for producing the pneumoviral virions and for using the virions in the treatment or prevention of pneumoviral infection and disease. A preferred pneumoviral virion is a virion of Respiratory Syncytial Virus in which preferably the gene for the G attachment protein is inactivated and complemented in trans.Type: GrantFiled: December 24, 2004Date of Patent: August 18, 2015Assignee: De Staat der Nederlanden, Vert. Door de Minister Van VWSInventors: Willem Luytjes, Myra Noorely Widjojoatmodjo
-
Publication number: 20100291035Abstract: The invention relates to pneumoviral virions comprising a viral genome that has a mutation in a gene coding for a protein that is essential for infectivity of the pneumovirus, whereby the mutation causes a virus produced from only the viral genome to lack infectivity, and whereby the virion comprises the protein in a form and in an amount that is required for infectivity of the virion. The invention also relates to methods for producing the pneumoviral virions and for using the virions in the treatment or prevention of pneumoviral infection and disease. A preferred pneumoviral virion is a virion of Respiratory Syncytial Virus in which preferably the gene for the G attachment protein is inactivated and complemented in trans.Type: ApplicationFiled: December 24, 2004Publication date: November 18, 2010Applicant: DE Staat Der Nederlanden, Vertegenwoordigd Door de Minister Van Volksgezondheil, Welzijn en SprotInventors: Willem Luytjes, Myra Noorely Widjojoatmodjo
-
Patent number: 7521058Abstract: The invention relates to vaccines used in the eradication or control of pestivirus infections, particularly those used in pigs or ruminants. The invention provides nucleic acid, pestivirus-like particles and a pestivirus vaccine, comprising the nucleic acid or particles, which is capable of eliciting a proper immune response without having the ability to spread throughout the vaccinated animal, thereby avoiding the negative consequences of viral spread. Preferably, the immune response allows for serological discrimination between vaccinated animals and wild-type pestivirus infected animals.Type: GrantFiled: March 21, 2005Date of Patent: April 21, 2009Assignee: ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V.Inventors: Myra Noorely Widjojoatmodjo, Robertus Jacobus Maria Moormann, Petrus Antonius van Rijn
-
Publication number: 20020106641Abstract: Vaccines used in the eradication or control of pestivirus infections, particularly those vaccines used in pigs or ruminants. The invention provides nucleic acid, pestivirus-like particles and a pestivirus vaccine, including the nucleic acid or particles, which are capable of eliciting a proper immune response without the ability to spread throughout the vaccinated animal, thereby avoiding the negative consequences of viral spread. Preferably, the immune response allows for serological discrimination between vaccinated animals and wild-type pestivirus infected animals.Type: ApplicationFiled: September 7, 2001Publication date: August 8, 2002Inventors: Myra Noorely Widjojoatmodjo, Robertus Jacobus. M. Moormann